Transdermal Diagnostics, a spinout company from the University of Bath, has announced that it has received £1.1 million in funding after it developed technology for monitoring glucose levels. The technology which is a wearable patch allows people with diabetes to painlessly and non-invasively monitor their blood glucose levels which could slow down or even prevent the progression of the disease.
Dr Ilie, chief scientific officer and director at Transdermal Diagnostics, said: “Our wearable, affordable patch will appeal particularly to people living with Type-2 diabetes and those considered to be pre-diabetic."
“It has great market potential because no such technology currently exists on the market. Developing the patch needed a truly interdisciplinary approach, and it was only made possible by the latest advances across multiple fields, such as advanced nanomaterials, nano- and bio-technology, and machine learning-driven data analysis.
Dr Ilie added: “Scalable methods able to deliver a device like ours on a flexible platform were also essential.”
The fund has been made up of £800,000 in seed funding and a £300,000 grant from Innovate UK, an on-departmental public body operating at arm's length from the Government as part of the United Kingdom Research and Innovation organisation. The funding round was led by QUBIS, which specialises in innovation-focused spin-out companies, and includes Pioneer Group, Immetric, Bristol Private Equity Club and Science Angel Syndicate.
Professor Richard Guy, company director, Transdermal Diagnostics added: “The spin-out of Transdermal Diagnostics provides the impetus to develop a revolutionary, affordable and needle-free glucose monitoring technology to inhibit or even arrest the progression of diabetes, enabling those living with the disease to safely and effectively manage and control their blood sugar levels.”
